DEVELOPMENT OF VACCINE AGAINST CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIA
Asian Journal of Advances in Medical Science, Volume 3, Issue 2,
The pandemic declaration of Covid-19 infection by World Health Organization (WHO) and ensuing boundless morbidities and mortalities in practically all nations of the world prompted the innovative work to discover an immunization against SARS-CoV2 infection. Typically any new vaccine takes 10–15 y time. In pandemic circumstance, the whole cycle of vaccine development including clinical preliminaries gets shortened and optimized to 10–14 month time. i.e. the quest for vaccine against Covid-19 is going on at a high speed coming with the good news of two vaccines Covishield and Covaxin. This review aims at highlighting the present stages of development of vaccinesin Indian scenario.
How to Cite
Available:https://doi.org/10.1056/ NEJMe2001126 PMID: 31978944.
Wang C. et al. A novel coronavirus outbreak of global health concern. Lancet; 2020.
Guan W. j. et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.
Guan WJ. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med; 2020.
Chen H. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–15.
Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513.
Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529−536.
Bhatraju PK. et al. Covid-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine; 2020.
Zhang W. et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386.
Van Doremalen N. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med; 2020.
Li Q. et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med; 2020.
Yang Y. et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv; 2020.
Porcheddu R. et al. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(2):125–8.
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet; 2020.
Lu X. et al. SARS-CoV-2 Infection in Children. N Engl J Med; 2020.
Schmid MB et al. COVID-19 in pregnant women. Lancet Infect Dis; 2020.
Rouse BT, Sehrawat S. Immunity and immunopathology to Viruses: What Decides the Outcome? Nat. Rev. Immunol. 2010;10:514−526.
Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010;10:338−349.
Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis; 2020.
Juno JA. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428−1434.
Dhama K. et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccine Immunotherpy; 2020.
Ning et al. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology; 2020.
Le Thanh T et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19: 305–6.
Le Tung. et al. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020;19(5):305–306.
Gupta V et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology. 2006;347(1):127–139.
Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;495–500.
COVID-19 vaccine. Vaccine information, ICMR New Delhi - COVID-19 Vaccine; 2020.
Panacea Biotec, Refana Announce Landmark Collaboration for Covid- 19 Vaccine. Panacea Biotec; 2020.
Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet. 2020;395(10239):1751-1752.
Douglas RG, Samant VB. The vaccine industry. In: Plotkins SA, Orenstein WA, Offit PA, editors. Vaccine. 6th ed. China: Saunders Elsevier. 2013;33–43.
Lauer SA. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine; 2020.
Abstract View: 2617 times
PDF Download: 1590 times